MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Whole exome sequencing of 67 Swedish Parkinson patients identifies a family with VPS35 D620N

    E. Kafantari, A. Puschmann (Lund, Sweden)

    Objective: To determine the usefulness of WES in the diagnostic evaluation of Parkinson’s disease (PD) patients and to set up computational pathways for the identification…
  • 2023 International Congress

    Access-PD – a ‘next generation’ registry to accelerate Parkinson’s disease research

    Y. Chang, A. Noyce (London, United Kingdom)

    Objective: To establish an integrated and fully remote registry for Parkinson’s disease (PD) in England, that leverages both electronic health records (EHR) and electronic patient-reported…
  • 2023 International Congress

    Multiple N-of-1 trials to investigate hypoxia-based treatment in Parkinson’s disease: safety and short-term effects

    J. Janssen Daalen, M. Meinders, F. Giardina, S. Mathur, P. Ainslie, D. Thijssen, B. Bloem (Nijmegen, Netherlands)

    Objective: In this study, we describe the safety and short-term effects of the first hypoxia-based treatment trial in Parkinson’s disease by deploying a personalized multiple…
  • 2023 International Congress

    Usability of Parkinson’s KinetiGraph in deep brain stimulation for essential tremor

    E. Jiltsova, D. Nyholm (Uppsala, Sweden)

    Objective: To estimate whether Parkinson’s KinetiGraph (PKG) can be useful in quantifying tremor severity in patients with essential tremor (ET) before and after treatment with…
  • 2023 International Congress

    Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase)

    L. Guedes, D. Hilt, M. Fonseca, I. Peixoto, H. Gama (Coronado, Portugal)

    Objective: To describe the safety profile and tolerability of BIA-28-6156 observed during phase 1 clinical trials. Background: BIA-28-6156 is a novel allosteric activator of beta-glucocerebrosidase…
  • 2023 International Congress

    Impact of Image-Guided Programming (IGP) in Bilateral STN Deep Brain Stimulation on Programming Time and Setting Outcomes

    J. Aldred, T. Zesiewicz, M. Okun, J. Ramirez-Castaneda, L. Verhagen-Mehtman, C. Luca, R. Ramdhani, J. Durphy, Y. Bezchlibnyk, J. Carlson, K. Foote, S. Sani, A. Papanastassiou, J. Jagid, D. Weintraub, J. Pilitsis, B. Reese, L. Chen, R. Jain (Spokane, USA)

    Objective: To determine if an image-guided programming (IGP) tool can enable shorter initial Deep Brain Stimulation (DBS) programming sessions and evaluate continued chronic use of…
  • 2023 International Congress

    Sleep disorders in Parkinson’s disease patients. A case-control study.

    L. Rotaru, M. Cebuc, A. Lupușor, O. Grosu, S. Odobescu, O. Gavriliuc, I. Moldovanu (Chisinau, Republic of Moldova)

    Objective: To determine the quality of sleep, the type of sleep disorders and their correlations with motor impairment in Parkinson's disease (PD) patients. Background: Sleep…
  • 2023 International Congress

    Learnings from inaugural year of foundation sponsored genetic counseling and testing program for Spinocerebellar Ataxia (SCA) types 1, 2, and 3

    K. Trace, N. Beck, L. Moore (Minneapolis, USA)

    Objective: To describe volume, genetic results, and participant perceptions of foundation sponsored genetic counseling and testing program for SCA 1, 2, and 3. Background: Molecular…
  • 2023 International Congress

    Caregiver burden in Parkinson disease: an updated scoping review

    J. Corcoran, W. Aamodt, S. Seshadri, M. Mirham, A. Job, S. Lettenberger, B. Kluger (Rochester, USA)

    Objective: We performed a scoping review to describe caregiver burden in Parkinson disease (PD) and build on the evidence provided by Mosely at al. [1]…
  • 2023 International Congress

    Combination COMT inhibitor with Levodopa reduces consumption of vitamin B6

    D. Kamiyama, N. Nishikawa, S. Ueno, C. Abe, T. Hatano, N. Hattori (Tokyo, Japan)

    Objective: To investigate changes in Levodopa (LD) pharmacokinetics and changes in homocysteine, vitamin B6, and vitamin B12 in Parkinson's disease (PD) patients receiving LD formulations…
  • « Previous Page
  • 1
  • …
  • 274
  • 275
  • 276
  • 277
  • 278
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley